Meridigen Biotech Co., Ltd.
π¨π³China
Clinical Trials
6
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)β’ Click on a phase to view related trials
Phase 1
6 (100.0%)Mesenchymal Stem Cells for The Treatment of Frailty Syndrome
Phase 1
Recruiting
- Conditions
- Frailty Syndrome
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Meridigen Biotech Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04914403
- Locations
- π¨π³
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan
Mesenchymal Stem Cells for The Treatment of Knee Osteoarthritis (KOA).
Phase 1
Recruiting
- Conditions
- Osteoarthritis, Knee
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Meridigen Biotech Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT04893174
- Locations
- π¨π³
Taipei Medical University Hospital, Taipei, Taiwan
Mesenchymal Stem Cells for The Treatment of Acute Respiratory Distress Syndrome (ARDS)
Phase 1
Not yet recruiting
- Conditions
- Acute Respiratory Distress Syndrome
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Meridigen Biotech Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04347967
- Locations
- π¨π³
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan
Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease
Phase 1
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease Moderate
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Meridigen Biotech Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT04206007
- Locations
- π¨π³
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan
Mesenchymal Stem Cells for The Treatment of Acute Ischemic Stroke
Phase 1
Recruiting
- Conditions
- Acute Ischemic Stroke
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Meridigen Biotech Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT04097652
- Locations
- π¨π³
Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare., New Taipei City, Taiwan
- Prev
- 1
- 2
- Next
News
No news found